Completed PHASE3 INTERVENTIONAL NCT00382889

As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma

Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.

Sponsor: Chiesi Farmaceutici S.p.A.

Conditions Asthma

Interventions beclomethasone beclomethasone/salbutamol combination salbutamol

Updated 6 times since 2017 Last updated: Jul 30, 2020 Started: Aug 31, 2002 Completion: Sep 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00382889, this PHASE3 trial focuses on Asthma and remains completed. Sponsored by Chiesi Farmaceutici S.p.A., it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Sep 2020 [monthly]

Completed PHASE3

First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chiesi Farmaceutici S.p.A.

Data source: Chiesi Farmaceutici S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bialystok, Poland , Bielsko-Biala, Poland , Catania, Italy , Ferrara, Italy , Genova, Italy , Krakow, Poland , Lòdz, Poland , Lódz, Poland , Mataró, Spain and 8 more locations